Zoetis Inc. (ZTS) Stake Increased by Comerica Securities Inc.
Comerica Securities Inc. grew its holdings in Zoetis Inc. (NYSE:ZTS) by 2.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,508 shares of the company’s stock after buying an additional 260 shares during the quarter. Comerica Securities Inc.’s holdings in Zoetis were worth $657,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after buying an additional 230 shares during the period. Guardian Life Insurance Co. of America lifted its holdings in shares of Zoetis by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares during the period. Almanack Investment Partners LLC. acquired a new stake in shares of Zoetis in the 2nd quarter valued at approximately $119,000. Assetmark Inc. lifted its holdings in shares of Zoetis by 4.6% in the 1st quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after buying an additional 85 shares during the period. Finally, Point72 Asia Hong Kong Ltd acquired a new stake in shares of Zoetis in the 1st quarter valued at approximately $111,000. 93.31% of the stock is owned by institutional investors and hedge funds.
Several research firms have recently commented on ZTS. BidaskClub raised Zoetis from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Cowen and Company set a $70.00 price target on Zoetis and gave the company a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 price target on shares of Zoetis in a report on Wednesday, September 6th. Deutsche Bank AG reissued a “buy” rating and issued a $65.00 price target (up from $62.00) on shares of Zoetis in a report on Monday, July 17th. Finally, Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a report on Tuesday, June 20th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $65.44.
Zoetis Inc. (NYSE:ZTS) traded down 0.08% during trading on Friday, reaching $65.20. The company’s stock had a trading volume of 2,115,398 shares. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $65.83. The firm has a 50-day moving average price of $62.29 and a 200-day moving average price of $59.39. The firm has a market capitalization of $31.89 billion, a P/E ratio of 36.86 and a beta of 1.02.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting analysts’ consensus estimates of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The company had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the prior year, the firm earned $0.49 EPS. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, equities analysts anticipate that Zoetis Inc. will post $2.34 EPS for the current fiscal year.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.